Latest Breaking News On - Bioaegis therapeutics inc - Page 5 : comparemela.com

BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection

BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Steven cordovanoChristine laganaSusan levinsonBiomedical advanced researchUs department of healthHuman servicesOffice of theBioaegis therapeutics incDevelopment authorityDivision of researchAssistant secretaryHost directed therapySolving sepsisRegulates inflammation without suppressing immuneAegis therapeuticsகிறிஸ்டின் லகனா

Study Identifies New Role of BioAegis Inflammation Regulator Gelsolin Relevant for a Range of Inflammatory Diseases

Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases April 08, 2021 18:58 ET | Source: BioAegis Therapeutics BioAegis Therapeutics Morristown, New Jersey, UNITED STATES Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell inflammatory cytokines. MORRISTOWN, N.J., April 08, 2021 (GLOBE NEWSWIRE) BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced publication of new research entitled “ Inflammation Causes a Decrease in Gelsolin and Elevation of Interleukin-1β- Carrying Microparticles

Steven cordovanoSusan levinsonUniversity of maryland school medicineBioaegis therapeutics incAegis therapeutics incMaryland schoolGelsolin can preventDriven damageBlood vesselsChief executive officerBioaegis therapeuticsKey componentAegis therapeuticsசூசன் லெவின்சன்பல்கலைக்கழகம் ஆஃப் மேரிலாந்து பள்ளி மருந்துஆதரவு சிகிச்சை இன்க்

BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Tarragona joanAntonio castroSteven cordovanoChristine laganaSandra parraUniversitari sant joanVictor babeSusan levinsonSant joan university hospital in reusBioaegis therapeutics incWorld health organizationHospital universitari sant joan de reusHospital universitari de tarragona joanSpitalul clinic de boli infecPneumoftiziologie dr victor babeSant joan university hospital

BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Tarragona joanAntonio castroSteven cordovanoChristine laganaSandra parraUniversitari sant joanVictor babeSusan levinsonSant joan university hospital in reusWorld health organizationBioaegis therapeutics incAegis therapeutics incHospital universitari sant joan de reusHospital universitari de tarragona joanSpitalul clinic de boli infecPneumoftiziologie dr victor babe

NIH and Other Independent Studies Confirm Low Levels of BioAegis Inflammation Regulator Protein, Gelsolin, Associated with COVID-19 Severity

NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity February 02, 2021 14:05 ET | Source: BioAegis Therapeutics BioAegis Therapeutics Morristown, New Jersey, UNITED STATES MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported that low levels of gelsolin are associated with severity and organ failure in COVID-19 patients, with the lowest pGSN levels seen in patients who subsequently died. BioAegis is currently conducting a Phase 2 clinical trial of recombinant human plasma gelsolin (rhu-pGSN) in severe COVID-19 patients to supplement gels

Steven cordovanoChristine laganaNational institute of healthWorld health organizationBioaegis therapeutics incClinical centerAegis therapeutics incNational instituteFailure scores associatedLow gelsolinLarge scale multi omic analysisSequential organ failure assessmentBiomarkers can aidClinical classificationHost based approachBioaegi phase